Pharmacology of chronic oral daily administration of idarubicin

Haematologica

Volumn 82, Issue SUPPL.5, 1997, Pages 1-3

  Toffoli, Giuseppe ^a   Sorio, Roberto ^a   Aita, Paola ^a   Crivellari, Diana ^a   Corona, Giuseppe ^a   Rimondi, Gioia ^a   Bearz, Alessandra ^a   Stocco, Franco ^b   Robieux, Isabel ^a   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b PFIZER INC   (United States)

Author keywords

Chemotherapy; Idarubicin; Idarubicinol; Oral administration

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IDARUBICINOL;

BONE MARROW TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; METASTASIS; ORAL DRUG ADMINISTRATION;

EID: 6844242343     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994; 47:223-58.
2. Cersosimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clin Pharmacol 1992; 11:152-67.
3. Casazza AM, Di Marco A, Bonadonna G. Effects of modifications in position 4 of the chromophore or in position 4' of the aminosugar on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD, eds. Anthracyclines. Current status and new developments. New York: Academic Press; 1980. p. 403-30.
4. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.
5. Fukushima T, Ueda T, Uchida M, Nakamura T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol 1993; 57:121-30.
6. Capranico G, Riva A, Tinelli S, Dasdia T, Zunino F. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res 1987; 47:3752-6.
7. Bertelli G, Amoroso D, Pronzato P, Rosso R. Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors. Anticancer Res 1988; 8:645-6.
8. Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S, Vigevani A. Influence of lipophylicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anti-Cancer Drug Des 1991; 6:385-97.
9. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79:3267-73.
10. Toffoli G, Simone F, Gigante M, Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem Pharmacol 1994; 48:1871-81.
11. Ames MM, Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6:70-5.
12. Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol 1995; 36:223-6.
13. Toffoli G, Corona G, Simone F, Gigante M, De Angeli S, Boiocchi M. Cellular pharmacology of idarubicinol in multidrug LoVo Cell lines. Int J Cancer 1996; 67:129-37.
14. Camaggi CM, Strocchi E, Carisi P, et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992; 30:307-16.
15. Einhorn LH. Daily oral etoposide in the treatment of cancer Semin Oncol 1991; 18:43-7.
16. Lai GM, Chen Y-N, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991; 49:696-703.